FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
JUNE 2018

POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.
OPHTHALMOLOGY
PAPER-III
TIME: 3 HOURS OPH/J/18/26/III
MAX. MARKS: 100
IMPORTANT INSTRUCTIONS
This question paper consists of 10 questions divided into Part "A" and part each part
containing 5 questions.
Answers to questions of part A and part B are to be strictly attempted in separate answer sheet(s)
and the main supplementary answer sheet(s) used for each part must be tagged separately.
Answers to question(s) of Part A attempted in answer sheet(s) of part B or Vice versa shall not be
evaluated.
Answer sheets of Part A and Part B are not to be tagged together.
Part A and Part B should be mentioned only on the covering page of the respective answer sheets.
Attempt all questions in order.
Each question carries 10 marks.
Read the question carefully and answer to the point neatly and legibly.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space.
Answer all the parts of a single question together.
Start the answer to a question on a fresh page or leave adequate space between two answers.
Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
PART A
1. Clinical features and management of 3rd nerve palsy. 10
2. Uses of Mitomicin C in Ophthalmology
Mention its side effects
8+2
3. Ischemic optic neuropathy diagnosis and management. 5+5
4. Criteria for early glaucomatous visual field changes. 10
5. Macular hole Its causes, grading and management.

6. Keratoprosthesis:
Types
Indications
8+2
7. Clinical features of early and late branch retinal vein
occlusion.
Results of important trials in management of BRVO.
5+5
8. Surgical spaces of orbit.
Discuss different approaches to orbitotomy and management
of unilateral proptosis.

9. Types of multifocal IOLs
Case selection and basic principles for premium IOLs.
5+5
10. Causes of hyperfluorescence and blocked fluorescence in
Fluorescein angiography.
Fluroscein angiographic features in CSR.
5+5